MannKind reports 2021 revenue $75.4M, +16%; Afrezza Q4 record $11.3M; net loss widens

MANNKIND CORP

2022-FY EPS reported -$0.32 revenue$75,442,000

Total revenues 2021: $75.4M (+16% vs 2020); Afrezza net revenue $39.2M (+21% YoY)
Q4 Afrezza net revenue $11.3M (+13% vs Q4 2020); collaborations revenue $1.2M
Cash and investments $260.7M at Dec 31, 2021 vs $67.2M a year ago; includes $230M convertible note and ~$100M sale-leaseback
Full-year net loss $80.9M ($0.32/sh) vs $57.2M ($0.26/sh) in 2020; non-GAAP loss $61.7M ($0.25/sh)
Tyvaso DPI PDUFA deadline extended to May 2022; clofazimine Phase 1 trial commenced in 1Q 2022

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.